Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Hotgen Biotech CoSHSE:688068 -6.33%54 Days Payable is 196.44 as of Mar. 2026, which is 160% above its 10-year median of 75.57. GuruFocus rates SHSE:688068 with a GF Score™ of 54/100 and a GF Value™ of ¥35.96 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 702 Biotechnology companies, Beijing Hotgen Biotech Co ranks better than 69.52% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688068 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Beijing Hotgen Biotech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Hotgen Biotech Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Beijing Hotgen Biotech Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Beijing Hotgen Biotech Co's Days Payable falls into.
Beijing Hotgen Biotech Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Beijing Hotgen Biotech Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Hotgen Biotech Co (SHSE:688068) has a Days Payable of 196.44 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Beijing Hotgen Biotech Co and its competitors. This is 160% above median its historical median of 75.57. Over the past decade, Beijing Hotgen Biotech Co's Days Payable has ranged from 20.92 to 296.20. According to the industry distribution chart, Beijing Hotgen Biotech Co ranks #214 out of 702 companies in the Biotechnology industry, placing it in the top 30.5%.
Is Beijing Hotgen Biotech Co's Days Payable too high?
Beijing Hotgen Biotech Co's current Days Payable of 196.44 is 160% above median its 10-year median of 75.57. Over the past 10 years, this metric has ranged from a low of 20.92 to a high of 296.20. The Biotechnology industry median Days Payable is 113.10. Beijing Hotgen Biotech Co's value of 196.44 is 73.7% above this industry median. Based on the distribution chart, Beijing Hotgen Biotech Co ranks #214 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Beijing Hotgen Biotech Co has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Hotgen Biotech Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Hotgen Biotech Co ranks #214 out of 702 companies for Days Payable. This puts Beijing Hotgen Biotech Co in the upper half of its industry. The industry median Days Payable is 113.10. Beijing Hotgen Biotech Co's value of 196.44 is 73.7% above this benchmark. Historically, Beijing Hotgen Biotech Co's own Days Payable has ranged from 20.92 to 296.20 over the past decade. While the company's 10-year median is 75.57 vs. the industry median of 113.10, Beijing Hotgen Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Hotgen Biotech Co's current Days Payable of 196.44 is 73.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Beijing Hotgen Biotech Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Hotgen Biotech Co's current Days Payable is 196.44, which is 160% above median its own 10-year median of 75.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Hotgen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Hotgen Biotech Co (SHSE:688068) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥35.96, compared to a current price of ¥123.22 — trading 242.7% above its estimated fair value. The current Days Payable is 196.44, which is 160% above median its 10-year median of 75.57 and 73.7% above the Biotechnology industry median of 113.10. Beijing Hotgen Biotech Co's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Beijing Hotgen Biotech Co (SHSE:688068), the current Days Payable is 196.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Hotgen Biotech Co (SHSE:688068) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Hotgen Biotech Co stock appears to be overvalued.
The current stock price of ¥123.22 is trading 242.7% above its estimated GF Value™ of ¥35.96.
GuruFocus considers Beijing Hotgen Biotech Co to be Significantly Overvalued.
Key valuation signals for SHSE:688068:
Days Payable: 196.44 (160% above median its 10-year median of 75.57)
GF Value™: ¥35.96 vs. price of ¥123.22 (242.7% above fair value)
Industry Position: 73.7% above the Biotechnology median (#214 of 702)
No single metric tells the full story. See the SHSE:688068 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Hotgen Biotech Co Ltd is engaged in the development and manufacturing of innovative in-vitro diagnostic, point-of-care-testing and biodefense products.
54GF Score
Get the complete analysis for SHSE:688068
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688068 has been successfully added to your 
